Efficacy and safety of once-daily roflumilast cream 0.3% in patients with knee/elbow involvement: Pooled results from phase 3 trials (DERMIS-1 and DERMIS-2)

被引：0
|
作者：
Ferris, Laura K. [1 ]
Draelos, Zoe D. [2 ]
Hebert, Adelaide A. [3 ]
Lynde, Charles W. [4 ]
Pariser, David M. [5 ,6 ]
Papp, Kim A. [7 ,8 ]
Yamauchi, Paul S. [9 ,10 ]
Feng, Amy [11 ]
Higham, Robert C. [11 ]
Burnett, Patrick [11 ]
Berk, David R. [11 ]
机构：
[1] Univ Pittsburgh, Dept Dermatol, Pittsburgh, PA 15260 USA
[2] Dermatol Consulting Serv, High Point, NC USA
[3] UT Hlth McGovern Med Sch, Houston, TX USA
[4] Lynderm Res Inc, Markham, ON, Canada
[5] Eastern Virginia Med Sch, Norfolk, VA USA
[6] Virginia Clin Res Inc, Norfolk, VA USA
[7] Prob Med Res, Waterloo, ON, Canada
[8] K Papp Clin Res, Waterloo, ON, Canada
[9] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[10] Dermatol Inst & Skin Care Ctr Inc, Santa Monica, CA USA
[11] Arcutis Biotherapeut Inc, Westlake Village, VA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2022年 / 87卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
33468
引用
收藏
页码：AB162 / AB162
页数：1
相关论文
共 50 条
  • [41] Active lifestyle in patients with haemophilia a or b with and without inhibitors on once-daily subcutaneous concizumab prophylaxis: Results from the phase 3 explorer7 and explorer8 trials
    Jimenez-Yuste, Victor
    Chan, Anthony
    Obeid, Joyce
    Nielsen, Amalie Rhode Hogh
    Somasundarapandian, Reunka Devi
    Villarreal Martinez, Laura
    You, Chur Woo
    Windyga, Jerzy
    HAEMOPHILIA, 2024, 30 : 27 - 29
  • [42] Symptom Improvements with Once-Daily Opicapone in Patients with Parkinson's Disease and Motor Fluctuations: Results from a Phase 3, Randomized Clinical Trial (BIPARK-1)
    Lew, M.
    Hauser, R. A.
    Ferreira, J.
    Poewe, W.
    Rascol, O.
    Olson, K.
    Farahmand, K.
    Siegert, S.
    Rocha, J. F.
    Soares-da-Silva, P.
    Liang, G. S.
    MOVEMENT DISORDERS, 2019, 34 : S2 - S2
  • [43] Efficacy and Safety of Tolebrutinib Versus Teriflunomide in Relapsing Multiple Sclerosis: Results from the Phase 3 GEMINI 1 and 2 Trials
    Oh, Jiwon
    Arnold, Douglas L.
    Cree, Bruce A. C.
    Ionete, Carolina
    Kim, Ho Jin
    Sormani, Maria Pia
    Syed, Sana
    Chen, Yixin
    Maxwell, Christina
    Benoit, Patrick
    Turner, Timothy J.
    Wallstroem, Erik
    Wiendl, Heinz
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1145 - 1146
  • [44] Ozanimod as a once-daily oral therapy for Japanese patients with ulcerative colitis: results from the induction period of a Phase 2/3 study (J-True North)
    Matsuoka, K.
    Nakase, H.
    Fujii, T.
    Hisamatsu, T.
    Suzuki, Y.
    Watanabe, M.
    Uchikawa, Y.
    Goto, S.
    Fujimoto, G.
    Zhang, C.
    Hibi, T.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1295 - I1296
  • [45] Efficacy and Safety of ≤200 mg Avapritinib in Patients with Advanced Systemic Mastocytosis: Pooled Results from the Phase 1 EXPLORER and Interim Phase 2 PATHFINDER Studies
    Radia, Deepti
    DeAngelo, Daniel
    Deininger, Michael W.
    Reiter, Andreas
    Sen, Jayita
    Lin, Hui Min
    Dimitrijevic, Sasa
    Gotlib, Jason
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S367 - S368
  • [46] Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease History or Cardiovascular Risk Factors: Results of a Pooled Analysis of Phase 3 Clinical Trials
    Cook, William
    Bryzinski, Brian
    Slater, Jill
    Frederich, Robert
    Allen, Elsie
    POSTGRADUATE MEDICINE, 2013, 125 (03) : 145 - 154
  • [47] Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials
    Amy McMichael
    Seemal R. Desai
    Aamir Qureshi
    Shipra Rastogi
    Andrew F. Alexis
    American Journal of Clinical Dermatology, 2019, 20 : 267 - 276
  • [48] Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials
    McMichael, Amy
    Desai, Seemal R.
    Qureshi, Aamir
    Rastogi, Shipra
    Alexis, Andrew F.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2019, 20 (02) : 267 - 276
  • [49] Insights into the efficacy and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis across age quartiles: Pooled analyses from the Phase 3 reSURFACE 1 and reSURFACE 2 trials
    Elewski, Boni
    Han, George
    Rozzo, Stephen J.
    Gogineni, Ranga
    Schenkel, Brad
    Guenthner, Scott
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB57 - AB57
  • [50] Safety of guselkumab in patients with psoriatic arthritis through 1 year: Pooled findings from DISCOVER-1 and DISCOVER-2 phase 3 trials
    Ritchlin, Christopher T.
    Rahman, Proton
    Helliwell, Philip S.
    Boehncke, Wolf-Henning
    McInnes, Iain
    Gottlieb, Alice B.
    Kollmeier, Alexa P.
    Shawi, May
    Zhou, Bei
    Mease, Philip J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB151 - AB151
12345